You are here

  • Home
  • Archive
  • Volume 77, Issue 3
  • Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)

Article metrics

Article menu

Download PDFPDF

Clinical and epidemiological research
Extended report
Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)

 

Online download statistics by month:

Online download statistics by month: November 2017 to August 2023

AbstractFullPdf
Nov 2017365365196
Dec 201710591095764
Jan 2018510511302
Feb 2018838815314
Mar 2018799794369
Apr 2018462465142
May 2018399405148
Jun 201827427883
Jul 2018360360144
Aug 201828828896
Sep 2018300300110
Oct 2018257257105
Nov 201821821867
Dec 201822022085
Jan 2019266260106
Feb 201928226494
Mar 2019260246101
Apr 201920119175
May 201919118169
Jun 201917016656
Jul 201921219761
Aug 201920619270
Sep 201916215046
Oct 201922019469
Nov 201920519659
Dec 201917416256
Jan 202023221083
Feb 202019117980
Mar 202018717767
Apr 202026625278
May 2020198183131
Jun 202017515583
Jul 202023321659
Aug 202014714384
Sep 202019818896
Oct 202027626273
Nov 2020212190104
Dec 202017316451
Jan 202123021892
Feb 202115113561
Mar 202118918093
Apr 202116115250
May 202116215464
Jun 202115214258
Jul 202112011566
Aug 202115415078
Sep 202113212556
Oct 202115214165
Nov 202111411264
Dec 202114413657
Jan 202211011936
Feb 202215014153
Mar 202218519065
Apr 202214614956
May 202213413159
Jun 202213113456
Jul 202211611646
Aug 202217416364
Sep 202215314954
Oct 202212512550
Nov 202216315260
Dec 202211610641
Jan 202311811553
Feb 202314914050
Mar 202312912039
Apr 2023938936
May 202310810159
Jun 20231039834
Jul 202313012354
Aug 202314012645
Total15920154366590